BioGaia
99.05
SEK
-4.48 %
Less than 1K followers
BIOG B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-4.48%
-3.37%
-20.44%
-11.48%
-7.43%
-21.01%
+1.69%
-2.51%
+1,294.42%
BioGaia is a biotechnology company operating in the pharmaceutical industry and focuses on the development, manufacturing and distribution of probiotics for health and well-being. The company's products are aimed at individuals and healthcare institutions. The business is global with a primary presence in Europe, North America and Asia. BioGaia was founded in 1990 and is headquartered in Stockholm.
Read moreMarket cap
10.02B SEK
Turnover
154.32M SEK
Revenue
1.42B
EBIT %
29.76 %
P/E
28.46
Dividend yield-%
6.97 %
Financial calendar
18/7
2025
Interim report Q2'25
22/10
2025
Interim report Q3'25
All
Webcasts
Press releases
ShowingAll content types
Förändrat antal röster i BioGaia AB (publ)
Finansinspektionen: Flaggningsmeddelande i BioGaia AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Finansinspektionen: Flaggningsmeddelande i BioGaia AB
Finansinspektionen: Flaggningsmeddelande i BioGaia AB
Finansinspektionen: Flaggningsmeddelande i BioGaia AB
Årsstämma i BioGaia
Annual General Meeting of BioGaia

BioGaia, Audiocast with teleconference, Q1'25
BioGaia AB: Interim Management Statement January - March 2025
BioGaia AB: Delårsredogörelse januari - mars 2025
Kallelse till årsstämma i BioGaia AB (publ)
Notice to attend the Annual General Meeting of BioGaia AB (publ)
BioGaias Års- och hållbarhetsredovisning 2024 publicerad
BioGaia Annual and Sustainability Report 2024 published
Transition in BioGaia: Anatom Holding, a Switzerland-based long-term investment firm, becomes anchor shareholder
Ägarförändring i BioGaia: Anatom, ett Schweizbaserat långsiktigt investeringsbolag, blir ny huvudägare
